Try our beta test site

Research Study of Bipolar Mood Symptoms and Cognitive Problems

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2011 by Johns Hopkins University.
Recruitment status was:  Active, not recruiting
Stanley Medical Research Institute
Information provided by:
Johns Hopkins University Identifier:
First received: January 29, 2007
Last updated: May 18, 2012
Last verified: January 2011

This is a sixteen-week, randomized, double-blind add-on study of valacyclovir versus placebo in approximately 60 outpatients meeting diagnostic criteria for DSM-IV Bipolar I or II disorder, testing positive for HSV-1 and who have demonstrable cognitive impairment defined as a total score of less than 85 (one standard deviation from the normal range) on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Each patient will be randomized to double-blind treatment with either valacyclovir or placebo for sixteen weeks. All subjects will be maintained on a stable regimen of psychiatric drugs prescribed by their treating psychiatrist. Patients will be evaluated every 2 weeks by the treatment team and mood rating scales will be administered at each visit including the YMRS, PANSS and the MADRS. The RBANS will be administered again at 8 and 16 weeks. Both the treatment team and the patient will remain blinded during the course of the study. Following the active treatment phase, patients will receive treatment as clinically indicated.

Primary Hypothesis:

Valacyclovir will be superior to placebo in reducing cognitive symptoms associated with bipolar disorder in subjects who have been previously infected with Herpes Simplex virus I (HSV-1).

Secondary Hypothesis:

Valacyclovir will be superior to placebo in reducing mood symptoms associated with bipolar disorder in subjects who have been previously infected with HSV-1.

Condition Intervention Phase
Bipolar Disorder
Drug: Valacyclovir
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double Blind Placebo Controlled Study of Valacyclovir in Cognitive Impairment and Mood Symptoms of Bipolar Disorder

Resource links provided by NLM:

Further study details as provided by Johns Hopkins University:

Primary Outcome Measures:
  • The primary outcome measure will be The primary outcome measure will be the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). [ Time Frame: 16 weeks ]

Secondary Outcome Measures:
  • The secondary outcome measures will be the Young Mania Rating Scale (YMRS), the Positive and Negative Syndrome Scale (PANSS) and the Montgomery Asberg Depression Rating Scale (MADRS). [ Time Frame: 16 weeks ]

Estimated Enrollment: 60
Study Start Date: March 2007
Estimated Study Completion Date: October 2012
Estimated Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: Valacyclovir
Subjects take two 500 mg capsules twice daily for 16 weeks.
Other Name: Valtrex
Placebo Comparator: 2 Drug: Placebo
Subjects take two 500 mg capsules twice daily for 16 weeks.

  Show Detailed Description


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Be between the ages of 18-65
  • Have a diagnosis of Bipolar I or II disorder (as defined by DSM-IV)
  • Be in active treatment with an outpatient psychiatrist
  • Test positive for HSV1
  • Demonstrate cognitive impairment on the RBANS as defined by a total score of less than 85 (i.e. greater than one standard deviation below normal).

Exclusion Criteria:

  • Either pregnant or nursing
  • Have been diagnosed with any serious, unstable illnesses including HIV infection or other immunodeficiency condition, hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease and hypertension), endocrinologic, neurologic, immunologic, or hematologic disease. Illnesses that are currently well controlled and being treated are not grounds for exclusion.
  • Have a history of hypersensitivity or intolerance to valacyclovir or acyclovir
  • Meet criteria for DSM-IV substance abuse (except nicotine and caffeine) within the past 90 days
  • Had ECT (Electroconvulsive Therapy) within three months prior to randomization
  • Judged to be at serious suicidal risk; inability to provide informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00428298

United States, Maryland
Johns Hopkins University School of Medicine, Dept. of Psychiatry
Baltimore, Maryland, United States, 21207
Sponsors and Collaborators
Johns Hopkins University
Stanley Medical Research Institute
Principal Investigator: Jennifer L Payne, MD Johns Hopkins University
  More Information

Additional Information:
Responsible Party: Jennifer Payne, M.D., Johns Hopkins University School of Medicine Identifier: NCT00428298     History of Changes
Other Study ID Numbers: 06TGF-981 
Study First Received: January 29, 2007
Last Updated: May 18, 2012

Keywords provided by Johns Hopkins University:
Manic Depression

Additional relevant MeSH terms:
Bipolar Disorder
Bipolar and Related Disorders
Mental Disorders
Antiviral Agents
Anti-Infective Agents processed this record on February 27, 2017